CL2019003915A1 - Métodos de purificación de columna de vector aav. - Google Patents
Métodos de purificación de columna de vector aav.Info
- Publication number
- CL2019003915A1 CL2019003915A1 CL2019003915A CL2019003915A CL2019003915A1 CL 2019003915 A1 CL2019003915 A1 CL 2019003915A1 CL 2019003915 A CL2019003915 A CL 2019003915A CL 2019003915 A CL2019003915 A CL 2019003915A CL 2019003915 A1 CL2019003915 A1 CL 2019003915A1
- Authority
- CL
- Chile
- Prior art keywords
- chromatography
- purification methods
- column purification
- affinity
- aav
- Prior art date
Links
- 238000000746 purification Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 4
- 238000001042 affinity chromatography Methods 0.000 abstract 2
- 238000004440 column chromatography Methods 0.000 abstract 2
- 238000005571 anion exchange chromatography Methods 0.000 abstract 1
- 238000005277 cation exchange chromatography Methods 0.000 abstract 1
- 238000002270 exclusion chromatography Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527633P | 2017-06-30 | 2017-06-30 | |
| US201762531744P | 2017-07-12 | 2017-07-12 | |
| US201762567905P | 2017-10-04 | 2017-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003915A1 true CL2019003915A1 (es) | 2020-06-19 |
Family
ID=64742749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003915A CL2019003915A1 (es) | 2017-06-30 | 2019-12-30 | Métodos de purificación de columna de vector aav. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210079422A1 (enExample) |
| EP (1) | EP3658250A4 (enExample) |
| JP (3) | JP2020526190A (enExample) |
| KR (2) | KR102669561B1 (enExample) |
| CN (1) | CN111032176A (enExample) |
| AU (1) | AU2018291023B2 (enExample) |
| CA (1) | CA3068622A1 (enExample) |
| CL (1) | CL2019003915A1 (enExample) |
| CO (1) | CO2020000911A2 (enExample) |
| IL (1) | IL271745A (enExample) |
| MX (2) | MX2020000216A (enExample) |
| MY (1) | MY207534A (enExample) |
| PE (2) | PE20251545A1 (enExample) |
| PH (1) | PH12020500044A1 (enExample) |
| SG (1) | SG11201913157RA (enExample) |
| WO (1) | WO2019006390A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| US12565645B2 (en) * | 2019-04-11 | 2026-03-03 | Regenxbio Inc. | Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions |
| US12403164B2 (en) | 2019-09-30 | 2025-09-02 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| EP3919613B1 (en) * | 2020-06-05 | 2024-08-07 | Sartorius BIA Separations d.o.o. | Enhanced purification of adeno-associated virus to more effectively remove contaminating dna |
| KR20230074703A (ko) * | 2020-06-24 | 2023-05-31 | 바이오버라티브 테라퓨틱스 인크. | 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법 |
| US20220033782A1 (en) * | 2020-07-29 | 2022-02-03 | Pall Corporation | Adenovirus-associated viruses separation method |
| EP4229204A1 (en) | 2020-10-15 | 2023-08-23 | F. Hoffmann-La Roche AG | Nucleic acid constructs for simultaneous gene activation |
| KR20230085929A (ko) | 2020-10-15 | 2023-06-14 | 에프. 호프만-라 로슈 아게 | Va rna 전사를 위한 핵산 구조체 |
| JP7767029B2 (ja) * | 2021-05-28 | 2025-11-11 | ダイセン・メンブレン・システムズ株式会社 | 細胞外小胞の分離精製方法 |
| JP7716233B2 (ja) * | 2021-05-28 | 2025-07-31 | ダイセン・メンブレン・システムズ株式会社 | 微小有用物質の分離精製方法と分離精製装置 |
| PE20240359A1 (es) * | 2021-06-11 | 2024-02-27 | Spark Therapeutics Inc | Metodos de purificacion de columna vectorial aav |
| AU2022358612A1 (en) * | 2021-09-28 | 2024-04-11 | Kashiv Biosciences, Llc | An improved process of purification of fusion protein |
| CN114250222A (zh) * | 2021-12-08 | 2022-03-29 | 苏州博腾生物制药有限公司 | 一种从动物组织中提取aav dna的方法 |
| GB202117844D0 (en) * | 2021-12-09 | 2022-01-26 | Oxford Biomedica Ltd | Purification method |
| JP2023141423A (ja) * | 2022-03-24 | 2023-10-05 | 国立大学法人 東京大学 | ウイルスの精製方法 |
| WO2023198685A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Method for determining aav genomes |
| CN119256220A (zh) | 2022-05-23 | 2025-01-03 | 豪夫迈·罗氏有限公司 | 用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法 |
| EP4532737A1 (en) | 2022-06-03 | 2025-04-09 | F. Hoffmann-La Roche AG | Method for producing recombinant aav particles |
| KR20250036743A (ko) | 2022-07-14 | 2025-03-14 | 에프. 호프만-라 로슈 아게 | 재조합 aav 입자를 생산하는 방법 |
| JPWO2024024337A1 (enExample) * | 2022-07-28 | 2024-02-01 | ||
| EP4744752A1 (en) | 2022-09-12 | 2026-05-20 | Hoffmann La Roche | METHOD FOR SEPARING SOLID AND EMPTY AAV PARTICLES |
| EP4385618A1 (en) | 2022-12-16 | 2024-06-19 | Chiral Technologies Europe SAS | Composite material for bioseparations |
| IL322001A (en) | 2023-02-07 | 2025-09-01 | Hoffmann La Roche | Method for detecting antibodies to anti-AAV particles |
| EP4683676A1 (en) | 2023-03-21 | 2026-01-28 | F. Hoffmann-La Roche AG | Method for the production of recombinant aav particle preparations |
| KR20250172636A (ko) * | 2023-04-12 | 2025-12-09 | 씨티바 바이오프로세스 알＆디 에이비 | 크로마토그래피 시스템, 이의 용도, 및 아데노-연관 캡시드를 분리하는 방법 |
| WO2025168663A1 (en) | 2024-02-09 | 2025-08-14 | F. Hoffmann-La Roche Ag | Method for producing recombinant adeno-associated viral particles |
| TW202603164A (zh) * | 2024-04-07 | 2026-01-16 | 美商星火治療公司 | 用於腺相關病毒殼體變異體純化之組成物及方法 |
| WO2025252480A1 (en) | 2024-06-07 | 2025-12-11 | F. Hoffmann-La Roche Ag | Method for purifying plasmid dna |
| WO2026022064A1 (en) | 2024-07-22 | 2026-01-29 | F. Hoffmann-La Roche Ag | Novel aav rep orfs and rep polypeptides |
| WO2026037757A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | Modified aav particles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1944362T3 (en) * | 1997-09-05 | 2016-01-25 | Genzyme Corp | Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer |
| US6593123B1 (en) * | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| US7261544B2 (en) * | 2003-05-21 | 2007-08-28 | Genzyme Corporation | Methods for producing preparations of recombinant AAV virions substantially free of empty capsids |
| KR101812813B1 (ko) * | 2009-06-16 | 2017-12-27 | 젠자임 코포레이션 | 재조합 ａａｖ 벡터에 대한 개선된 정제 방법 |
| ES2680915T3 (es) * | 2010-01-28 | 2018-09-11 | The Children's Hospital Of Philadelphia | Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica |
| MX2018006682A (es) * | 2015-12-01 | 2018-09-26 | Spark Therapeutics Inc | Metodos escalables para producir vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspension libre de suero adecuado para su uso clinico. |
| US11015173B2 (en) * | 2015-12-11 | 2021-05-25 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV1 |
| ES2918998T3 (es) * | 2015-12-11 | 2022-07-21 | Univ Pennsylvania | Método de purificación escalable para AAVrh10 |
| WO2017100676A1 (en) * | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav8 |
| ES2896080T3 (es) * | 2016-03-31 | 2022-02-23 | Spark Therapeutics Inc | Procedimiento en columna totalmente escalable de preparación de VAAr |
-
2018
- 2018-06-29 SG SG11201913157RA patent/SG11201913157RA/en unknown
- 2018-06-29 CA CA3068622A patent/CA3068622A1/en active Pending
- 2018-06-29 AU AU2018291023A patent/AU2018291023B2/en active Active
- 2018-06-29 PE PE2025000717A patent/PE20251545A1/es unknown
- 2018-06-29 PE PE2019002713A patent/PE20200737A1/es unknown
- 2018-06-29 EP EP18823181.5A patent/EP3658250A4/en active Pending
- 2018-06-29 MY MYPI2019007880A patent/MY207534A/en unknown
- 2018-06-29 KR KR1020207002118A patent/KR102669561B1/ko active Active
- 2018-06-29 US US16/627,227 patent/US20210079422A1/en active Pending
- 2018-06-29 JP JP2019572175A patent/JP2020526190A/ja active Pending
- 2018-06-29 CN CN201880053245.7A patent/CN111032176A/zh active Pending
- 2018-06-29 KR KR1020247016903A patent/KR102879640B1/ko active Active
- 2018-06-29 WO PCT/US2018/040430 patent/WO2019006390A1/en not_active Ceased
- 2018-06-29 MX MX2020000216A patent/MX2020000216A/es unknown
-
2019
- 2019-12-29 IL IL271745A patent/IL271745A/en unknown
- 2019-12-30 CL CL2019003915A patent/CL2019003915A1/es unknown
-
2020
- 2020-01-03 PH PH12020500044A patent/PH12020500044A1/en unknown
- 2020-01-08 MX MX2024007103A patent/MX2024007103A/es unknown
- 2020-01-28 CO CONC2020/0000911A patent/CO2020000911A2/es unknown
-
2022
- 2022-11-07 JP JP2022177960A patent/JP2023029832A/ja active Pending
-
2024
- 2024-12-04 JP JP2024211621A patent/JP2025038906A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019006390A1 (en) | 2019-01-03 |
| EP3658250A4 (en) | 2021-10-27 |
| JP2023029832A (ja) | 2023-03-07 |
| JP2025038906A (ja) | 2025-03-19 |
| PE20251545A1 (es) | 2025-06-05 |
| KR102879640B1 (ko) | 2025-10-30 |
| MX2024007103A (es) | 2024-06-24 |
| MY207534A (en) | 2025-03-03 |
| KR20240093848A (ko) | 2024-06-24 |
| BR112019028299A2 (pt) | 2020-07-14 |
| CO2020000911A2 (es) | 2020-06-19 |
| MX2020000216A (es) | 2020-09-03 |
| CN111032176A (zh) | 2020-04-17 |
| AU2018291023B2 (en) | 2023-11-02 |
| EP3658250A1 (en) | 2020-06-03 |
| KR20200040749A (ko) | 2020-04-20 |
| PH12020500044A1 (en) | 2020-09-14 |
| JP2020526190A (ja) | 2020-08-31 |
| US20210079422A1 (en) | 2021-03-18 |
| KR102669561B1 (ko) | 2024-05-24 |
| SG11201913157RA (en) | 2020-01-30 |
| IL271745A (en) | 2020-02-27 |
| CA3068622A1 (en) | 2019-01-03 |
| RU2020103743A (ru) | 2021-07-30 |
| RU2020103743A3 (enExample) | 2021-09-30 |
| AU2018291023A1 (en) | 2020-02-06 |
| PE20200737A1 (es) | 2020-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020000911A2 (es) | Métodos de purificación de columna de vector aav | |
| WO2019241535A3 (en) | Anion exchange chromatography for recombinant aav production | |
| CL2021000517A1 (es) | Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
| CO2018011151A2 (es) | Proceso de producción de raav a base de columnas completamente escalable | |
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| EA202090540A1 (ru) | Ген, придающий устойчивость к патогенному грибу | |
| ECSP19005417A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
| MX392396B (es) | Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos. | |
| EA202091712A1 (ru) | МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ | |
| AU2018260998A2 (en) | Modulatory polynucleotides | |
| BR112016029318A2 (pt) | tratamento de mielomas | |
| CR20230026A (es) | Proteínas de fusión gdf15 y usos de estas (divisional 2018-0532) | |
| ECSP10010191A (es) | Anticuerpos antimesotelina y usos de los mismos | |
| PH12022551228A1 (en) | Trem2 antibodies and uses thereof | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| BR112019011462A2 (pt) | peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica. | |
| MX2017011189A (es) | Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos. | |
| BR112022012230A2 (pt) | Variantes de progranulina | |
| CU20170112A7 (es) | Variantes de polipeptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, así como procedimientos para la división de toxinas de fusarium | |
| PH12019501064A1 (en) | Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | |
| BR112017011226A2 (pt) | peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica | |
| EA201691834A1 (ru) | Новый способ очистки гонадотропина | |
| MX2021005435A (es) | Transgen abcb11 con codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 2 (pfic2). | |
| CY1125117T1 (el) | Ενωσεις μορφολινυλπυριδονης | |
| CL2021000930A1 (es) | Piridazinas novedosas |